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Introduction: Carotid Body Tumors (CBTs) are Paragangliomas (PGLs) located in the head and neck region
which usually do not cause overt neuroendocrine symptoms and hypertension. Matrix Metal-
loproteinases (MMPs) have shown a strong correlation between CBTs and their clinical behavior. Aim of
this study is to analyze the relationship between changes in arterial blood pressure and metal-
loproteinases levels after surgical resection of CBTs.
Methods: We performed a multicenter clinical study on 17 patients with benign and malignant CBTs (5
males; 12 females). Tumors were completely resected and biopsies, obtained at the time of surgery, were
lysed for Western blot analysis to determine MMPs levels in tissues. An enzyme-linked immune sorbent
assay (ELISA) kit was used to determine the concentration of MMPs in plasma ﬂuid.
Blood pressure values were measured at admission and at 10 days after surgery.
Results: At the time of the admission, blood pressure values were higher in patients with CBTs respect to
control patients; moreover in patients with malignant CBTs blood pressure values were higher (P < 0.01)
respect to patients with benign CBTs. 10 days after the surgery, we documented a signiﬁcant decrease
(P < 0.01) in blood pressure values and in MMPs levels in all patients with CBTs.
Conclusion: These results suggest that, despite the CTBs are considered non-functional tumors, an
“underestimated” neuroendocrine activity on arterial blood pressure may be detected.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Paragangliomas (PGLs) are rare neuroendocrine tumors that
arise in sympathetic and parasympathetic paraganglia and derive
from neural crest cells. In 80e85% of cases, PLGs ared Surgical Science, University
ermaneto, 88100 Catanzaro,
by Elsevier Ltd. All rights reservedpheochromocytomas (PCCs), whereas 15e20% are located in extra-
adrenal chromafﬁn tissue [1]: Carotid Body Tumors (CBTs) are the
most common paraganglioma (PLG) in the head and neck [2].
Usually, PGLs are benign lesions and the development of
metastasis is uncommon (approximately 6%) [3,4]. CBTs have an
incidence of about 1 in 30,000 [2] and are mostly benign neoplasms
of the middle age [5] with a 5% of metastatic rate [6e8].
These tumors are often identiﬁed accidentally as a painless
slow-growing mass and diagnosis is delayed because of subtle
symptoms. Several studies have shown that hypertension, the main.
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it can be continuous, intermittent, and often paroxysmal in nature
with associated typical signs, such us palpitations, headache and
diaphoresis [9e12]; nevertheless, benign as well as malignant PLGs
located in the head and neck region, such us CBTs, usually do not
cause neuroendocrine symptoms and/or hypertension [13e17].
These tumors causes progressive symptoms such as dysphagia,
odynophagia, hoarseness of voice or cranial nerve deﬁcits because
of the strong proximity to the neck vascular, nervous and muscular
structures [2,18,19]. Matrix metalloproteinases (MMPs)are zinc-
dependent endopeptidases which degrade various components of
the extracellular matrix (ECM) and release growth factors and cy-
tokines that reside in the ECM [20]; ECM remodeling is regulated by
endogenous tissue inhibitors of metalloproteinases (TIMPs).
Through their enzymatic activity, MMPs play several roles in tumor
invasion and metastasis [21] and are involved in the pathogenesis
of major inﬂammatory [22] and vascular diseases [23e33]. Our
recent experience has shown a strong correlation between PLGs
(both benign and malignant neoplasms) and the expression of
MMPs [34] as well as recent studies have suggested that altered
expression and activity of MMPs, particularlyMMP-1, -2, -3, -9, may
be implicated in vascular remodeling of several cardiovascular
diseases [35e38].
In this study in patients with benign and malignant CBTs we
evaluated the levels of MMP-1, -2, -3, -9 in plasma and we corre-
lated these with the values of blood pressure at admission and after
surgical excision of the tumor.
2. Materials and methods
2.1. Study population and experimental protocol
We performed a multicenter clinical study, conducted between
January 2013 and December 2013 (1-year-period) with prior
approval from the Institutional Review Board at the University of
Catanzaro, in accordance with the Declaration of Helsinki and the
Guideline for Good Clinical Practice. Patients were enrolled in
Department of Medical and Surgical Science of University “Magna
Graecia” of Catanzaro, Department of General, Geriatric, Oncologic
Surgery and Advanced Technologies of University of Naples “Fed-
erico II”, Unit of Vascular and Endovascular Surgery, Department of
Surgical, Anesthesiological and Radiological Sciences, University of
Ferrara, Sant'Anna Hospital of Catanzaro and Unit of Vascular and
Endovascular Surgery, Annunziata Hospital, Cosenza. Before the
beginning of the study, all participants provided awritten informed
consent.
The patients with diagnosis of CBTs were enrolled at the time of
our previous study [34].
2.2. Experimental protocol
We performed a retrospective analysis of data from medical
records of 14 previously enrolled patients with CBTs [34]. Moreover,
we performed also a prospective study in patients enrolled in 2013.
As previously described [34], patients eligible for the study were
of both sexes, from 20 up to 70 years, with diagnosis of benign and
malignant vascular tumors. Tumors were completely resected ac-
cording to the recent surgical technique and anatomo-pathological
examination of operative sample was performed. Biopsies obtained
at the time of surgery were lysed for Western blot analysis in
agreement with our previous studies [13e14,17,19], anti-MMPs
monoclonal antibodies were used and results were expressed as
arbitrary units in agreement with our previous papers
[23,25,26,29,31]. All experiments were performed in triplicate. In
agreement with our previous papers [23,25,26,29,31], an enzyme-linked immune sorbent assay (ELISA) kit was used to determine the
concentration of MMPs in plasma ﬂuid. A commercially available
sandwich ELISA kit with an MMPs monoclonal antibody was used
to determine plasma MMP-s levels. According to recent classiﬁca-
tion [39], in all patients the valuation of blood pressure before
surgical excision and 10 days later was performed (Table 2).
A further group of healthy volunteer patients (Group II) of both
sexes were enrolled and represented the control group. As previ-
ously described [34], in these patients we take the blood samples in
order to evaluate through the ELISA test the MMPs values and we
also evaluated the blood pressure values. For both Groups I and II
medical history was recorded, and clinical examination, laboratory
ﬁndings, duplex ultrasonography were performed.
2.3. Statistical analysis
All data are expressed as mean ± standard error medium
(SEM). Student's t test was performed in order to analyze the
difference between each group with their control. Anova test was
used to evaluate the difference between the groups. Differences
identiﬁed by ANOVA were pinpointed by unpaired Student's t test.
The test of Pearson was used to evaluate the correlation between
plasma MMPs levels and blood pressure values. The threshold of
statistical signiﬁcance was set at *P < 0.05. SPSS (SPSS Inc., Chi-
cago, USA) software was used for statistical analyses. We deﬁned
this study as exploratory, therefore we did not determine a power
calculation. In this light, these results could only be labeled as
exploratory.
3. Results
In the present multicenter study we enrolled 3 patients (1 male
and 2 females) with carotid benign paraganglioma, while data from
14 patients (4 males and 10 females; 11 patients with benign par-
aganglioma and 3 patients with malignant one) enrolled in a pre-
vious study were analyzed. Moreover, 3 health patients were
enrolled in control group (1 male and 2 females).
At the time of the admission, blood pressure values were higher
in patients with CBTs respect to control patients (data not shown);
moreover in patients with malignant CBTs (numbers 15e17) blood
pressure values were higher (P < 0.01) respect to patients with
benign CBTs (numbers 1e14).
ELISA ﬁndings performed on blood samples take at the time of
admission, revealed signiﬁcantly higher levels (P < 0.01) of MMP-1,
MMP-2, MMP-3, MMP-8 and MMP-9 in patients with para-
ganglioma respect to control patients (data not shown). Moreover,
patients with malignant CBTs (patient numbers 15e17) showed
signiﬁcantly higher levels (P < 0.01) of MMP-1, MMP-2 and MMP-3,
respect to patients with benign CBTs (patient numbers 1e14)
(Table 1). No signiﬁcant differences were documented in plasma
values of MMP-7 and MMP-13 between patients with malignant
(numbers 15e17) and patients with benign ones (patient numbers
1e14) (Table 1).
An increased expression (P < 0.01) of MMP-1, MMP-2 andMMP-
3, but not in MMP-7, MMP-8 and MMP-9, were recorded through
western blot in patients with malignant paraganglioma respect to
patients with benign one (data not shown). Finally, blood pressure
evaluation and Elisa test performed 10 days after the surgery,
documented a signiﬁcant decrease (P < 0.01) in blood pressure
values and in MMPs levels, without differences between patients
with malignant CBTs (numbers 15e17) and patients with benign
one (numbers 1e14) (Table 2). Finally using Pearson's test we
documented a signiﬁcant correlation (P < 0.01) between blood
pressure (systolic, diastolic and differential) andMMPs, particularly
with MMP1.
Table 1
Blood pressure values (mmHg) and plasmamatrix metalloproteinases levels (ng/mL) at the time of admission in patients with benign (numbers 1e14) andwithmalignant CBTs
(number 15e17).
Patients PAS PAD DBP MMP1 MMP2 MMP3 MMP7 MMP8 MMP9 MMP13
1 130 86 44 3.7 690 9.1 0.38 15 88 0.86
2 134 88 46 3.9 695 8.7 0.4 15.2 92 0.84
3 132 88 44 4.1 688 8.9 0.39 15.4 92 0.83
4 130 86 44 3.4 702 9.5 0.37 15.1 89 0.88
5 130 84 46 3.6 711 9.1 0.35 15.1 91 0.87
6 138 89 49 3.8 695 9.8 0.49 15.8 99 0.88
7 134 86 48 3.2 693 8.2 0.37 15.5 94 0.85
8 132 88 44 3.9 702 9.2 0.39 15.3 92 0.83
9 130 86 44 4.1 708 9 0.37 14.9 90 0.81
10 136 89 49 3.6 713 9.5 0.48 15.9 95 0.82
11 135 87 48 3.8 697 9.1 0.42 15.3 93 0.87
12 130 87 43 3.7 689 9.21 0.35 15.7 87 0.84
13 134 88 46 3.8 710 9.05 0.39 16 89 0.86
14 132 86 46 3.7 695 9.16 0.38 14.9 90 0.88
15 158 98 60 4.7 916 16.9 0.9 16.2 89 0.91
16 162 102 60 5.1 927 17.3 0.94 15.9 93 0.92
17 154 94 60 5.3 911 16.5 0.91 16.3 94 0.88
BPS: systolic blood pressure; BPD: diastolic blood pressure; DBP: differential blood pressure; MMP: matrix metalloproteinases.
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Carotid body is a physiologically important paraganglion that
responds to hypoxia by detecting the hydrogen ion concentration
and feeding back to the respiratory center in the brainstem: it
sends impulses to the external intercostal muscles, diaphragm,
vasculature, and heart, thus reﬂexively increasing the rate and
depth of ventilation, as well as slightly increasing blood pressure
and heart rate [40]. CBT often present as slow growing, non-
tender neck masses located just anterior to the sternocleido-
mastoid muscle at the level of the hyoid. As previously described
[2], tumor is mobile in the lateral plane but its mobility is limited
in the cephalo-caudal direction [41], tumor mass may transmit
the carotid pulse or demonstrate a bruit or thrill [42] and may
causes compression and inﬁltration of cranial nerves (VII-
eIXeXXIeXII). CBTs are usually classiﬁed using the criteria
described by Shamblin and co-workers [2,43]. These tumors are
mainly nonfunctional; some CBTs may be functional and convey
catecholamine, such as norepinephrine, epinephrine, dopamine,
and serotonin, or trigger catecholamine-induced signs and
symptoms which can produce cardiovascular and metabolic
symptoms such as palpitations, hypertension, stroke, shortness
of breath and weight loss [44e49]. Evidence of increasedTable 2
Blood pressure values (mmHg) and plasma matrix metalloproteinases levels (ng/mL) 10
CBTs (number 15e17).
Patients PAS PAD DBP MMP1 MMP2
1 126 82 44 2.88 483
2 128 84 44 2.58 488
3 126 84 42 2.62 485
4 124 81 43 2.63 478
5 122 83 39 2.55 480
6 128 88 40 2.9 487
7 126 84 42 2.75 486
8 130 82 48 2.76 482
9 128 80 48 2.85 481
10 126 82 44 2.86 493
11 122 85 37 2.83 485
12 128 83 45 2.86 486
13 130 84 46 2.62 488
14 124 82 42 2.69 487.55
15 129 88 41 2.66 480.68
16 132 89 43 2.62 483.23
17 130 83 47 2.88 490.21
BPS: systolic blood pressure; BPD: diastolic blood pressure; DBP: differential blood pressendocrine activity demonstrates only1e3% of CBTs [50] and high
blood pressure is the common feature.
Our study showed interesting data:
 all enrolled patients showed a signiﬁcant reduction of blood
pressure after the surgical excision of the tumor, especially
those who had, at admission, high blood pressure according to
recent classiﬁcations [39];
 MMP-1, -2, -3, -9 were the protease mostly expressed in CBTs
and, at the same time, those which, according to literature
[35e38], have been involved in the pathophysiological pro-
cesses that hypertension induces on vessels;
 at admission, MMP-1, -2, -3, -9 concentration were higher in
patients with higher blood pressure;
 evaluation of MMP-1, -2, -3, -9 concentration after surgery
showed an evident reduction of their levels;
 reduction of MMPs concentration within 7e10 days (after sur-
gery) was consensual and parallel with the reduction of blood
pressure (P < 0.005).
These results suggest that, despite the CTBs of our study are of
non-functional tumors, an “underestimated” neuroendocrine ac-
tivity was detected.days after the surgery in patients with benign (numbers 1e14) and with malignant
MMP3 MMP7 MMP8 MMP9 MMP13
7.2 0.35 8.8 88 0.78
7.4 0.37 9.2 94 0.804
7.2 0.33 9.4 92 0.803
6.9 0.32 8.7 90 0.77
7.1 0.31 8.9 87 0.82
7.7 0.38 9.8 95 0.815
7.4 0.36 9.4 94 0.816
7.2 0.33 9.1 92 0.81
7 0.31 8.89 89 0.789
7.65 0.38 9.8 98 0.8
7.5 0.36 9.5 95 0.82
7.3 0.351 8.85 94.7 0.787
7.4 0.375 9.3 91.5 0.798
7.2 0.332 9.48 92.2 0.806
7.3 0.324 8.75 93.5 0.787
7.28 0.315 9.2 93.65 0.812
7.65 0.378 8.45 95.8 0.803
ure; MMP: matrix metalloproteinases.
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